DOLLAR/YEN DIPS BELOW 150, LAST AT 149.95, UP 1.7%
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: HIGHLIGHTS OF ROUND THREE MATCHES AT THE ATP 1000 SHANGHAI MASTERS COMPLETE SHOTIST TO FOLLOW SHOWS: SHANGHAI, CHINA (OCTOBER 6, 2025) (ATP MEDIA / IMG – See restrictions before use) ALEX DE MINAUR (AUSTRALIA) V KAMIL MAJCHRZAK (POLAND) FELIX AUGER-ALIASSIME (CANADA) V JESPER DE JONG (NETHERLANDS) DENIS SHAPOVALOV (CANADA) V JIRI LEHECKA (CZECH REPUBLIC) NUNO BORGES (PORTUGAL) V JUNCHENG SHANG (CHINA) STORY: Alex de Minaur and Felix Auger-Aliassime advanced to the fourth round of the Shanghai Masters on Monday (October 6), each claiming straight-sets victories to continue their strong starts at the ATP Masters 1000 event. Seventh-seeded De Minaur defeated Kamil Majchrzak 6-1 7-5, while 12th seed Auger-Aliassime overcame Jesper de Jong 6-4 7-5. De Minaur broke Majchrzak's serve five times to secure his Tour-leading 36th hard-court win of the season. Despite briefly trailing 3-4 in the second set, the Australian recovered with two consecutive breaks and remains in contention for a spot at the ATP Finals for the second straight year. Auger-Aliassime also maintained his perfect start in Shanghai, dispatching de Jong without losing a set across his first two matches. The Canadian is looking to bolster his season after a challenging year and will seek to continue his momentum in the next round. De Minaur is set to face Portugal's Nuno Borges, who defeated home favorite Shang Juncheng 7-6(5) 4-6 6-3 to reach the fourth round at a Masters 1000 event for the fourth time in his career. Meanwhile, Jiri Lehecka knocked out Canadian Denis Shapovalov 6-4 6-4 and will next face either third seed Alexander Zverev or France's Arthur Rinderknech. (Production: Suramya Kaushik)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Reuters) -Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a deal worth up to $555 million. Under the deal, AstraZeneca will get exclusive rights to develop therapies that target immune system-related disorders. The Anglo-Swedish pharmaceutical major will also get the right to sell the treatments, if they get approved, while Algen will get upfront and milestone payments. AstraZeneca has been advancing its cell and gene therapy capabilities through acquisitions and partnerships as it works towards its target of $80 billion in sales by 2030. Globally too, drugmakers are increasingly turning to AI for drug development. The drugmaker in March agreed to buy Belgian biotech EsoBiotec for up to $1 billion, gaining access to technology that modifies immune cells directly inside the body. Monday's deal, however, does not include AstraZeneca buying a stake in the company, Algen CEO and co-founder Chun-Hao Huang told Reuters in an interview. "Together with AstraZeneca's deep expertise in translational science and clinical development, we aim to uncover new biological insights to accelerate the development of novel therapies," Huang said. Algen was spun out from the lab at UC Berkeley, where biochemist Jennifer Doudna pioneered the CRISPR technology that won her the Nobel Prize. The biotech firm's AI platform, AlgenBrain, can map genes to disease outcomes, helping the companies decide their development focus for therapies. The Financial Times had first reported the news. (Reporting by Raechel Thankam Job and Pushkala Aripaka in Bengaluru; Editing by Leroy Leo)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Reuters) -Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a deal worth up to $555 million. Under the deal, AstraZeneca will get exclusive rights to develop therapies that target immune system-related disorders. The Anglo-Swedish pharmaceutical major will also get the right to sell the treatments, if they get approved, while Algen will get upfront and milestone payments. AstraZeneca has been advancing its cell and gene therapy capabilities through acquisitions and partnerships as it works towards its target of $80 billion in sales by 2030. Globally too, drugmakers are increasingly turning to AI for drug development. The drugmaker in March agreed to buy Belgian biotech EsoBiotec for up to $1 billion, gaining access to technology that modifies immune cells directly inside the body. Monday's deal, however, does not include AstraZeneca buying a stake in the company, Algen CEO and co-founder Chun-Hao Huang told Reuters in an interview. "Together with AstraZeneca's deep expertise in translational science and clinical development, we aim to uncover new biological insights to accelerate the development of novel therapies," Huang said. Algen was spun out from the lab at UC Berkeley, where biochemist Jennifer Doudna pioneered the CRISPR technology that won her the Nobel Prize. The biotech firm's AI platform, AlgenBrain, can map genes to disease outcomes, helping the companies decide their development focus for therapies. The Financial Times had first reported the news. (Reporting by Raechel Thankam Job and Pushkala Aripaka in Bengaluru; Editing by Leroy Leo)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
ZELENSKIY SAYS SUPPLIES OF U.S.-PRODUCED WEAPONS TO UKRAINE NOT AFFECTED BY U.S. GOVERNMENT SHUTDOWN
ZELENSKIY SAYS SUPPLIES OF U.S.-PRODUCED WEAPONS TO UKRAINE NOT AFFECTED BY U.S. GOVERNMENT SHUTDOWN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
PARIS (Reuters) -The Paris prosecutor's office said on Monday it was investigating Siri, Apple's voice assistant, after it received a complaint. Politico reported earlier on Monday that Apple is suspected of using users' recordings without their knowledge. (Reporting by Gabriel Stargardter; Writing by Makini Brice)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
PARIS (Reuters) -The Paris prosecutor's office said on Monday it was investigating Siri, Apple's voice assistant, after it received a complaint. Politico reported earlier on Monday that Apple is suspected of using users' recordings without their knowledge. (Reporting by Gabriel Stargardter; Writing by Makini Brice)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
* Bestsellers include 'Rivals' and 'Riders' * 'Riders' was published in 1985 * 'Rivals' was made into a television series in 2024 * Agent said 'bonkbusters' stood test of time (Adds comment from agent's statement in paragraph 4, Cooper comments in paragraph 7 and 10) By Sarah Young and Sam Tabahriti LONDON, Oct 6 (Reuters) – Jilly Cooper, the British author of novels such as "Rivals" and "Riders" whose 1980s bestsellers were a blend of sex, satire and British snobbery, has died aged 88, her agent said in a statement on Monday. Cooper sold 11 million copies of her books in Britain alone. From the mid-1980s, her raunchy novels depicting the romantic adventures of an upper-class set of characters in the fictional county of Rutshire gained increasing commercial success. Last year, "Rivals" found a new generation of fans when it was made into a series for Disney+. Sales of books first published decades before shot up once again, as the themes of adultery and class rivalry thrilled younger audiences. "You wouldn’t expect books categorised as 'bonkbusters' to have so emphatically stood the test of time but Jilly wrote with acuity and insight about all things," Cooper's agent, Felicity Blunt at Curtis Brown, said in the statement. 'FAR LESS BONKING NOW' Born in Essex in 1937, Cooper was a newspaper columnist for the Sunday Times in the 1960s, commenting on marriage, sex and household chores, before she started writing novels in the 1970s. It was not until Riders in 1985 that she had her breakthrough. At the centre of the story was Rupert Campbell-Black, a handsome, ruthless showjumper and womaniser, who lives on his family's manor house in Rutshire. "There’s far less bonking now. People are so serious. I think we need more joy," Cooper said last year. Rutshire was inspired by Gloucestershire, where Cooper moved in the early 1980s. Amongst her social circle in that part of western England was Camilla Parker Bowles, now Queen Camilla, following her marriage to Prince Charles in 2005. Speaking on a podcast last year, Cooper was asked about Camilla's first husband, the army officer Andrew Parker Bowles. "He's been a great friend for a long time… so he's very like Rupert. He's beautiful and blond and stunning," she said, referring to the Rupert Campbell-Black character of her novels. Cooper wrote more than 40 books, many of them produced in a summerhouse at the bottom of her garden while she listened to classical music. She died after a fall on Sunday, her agent's statement said. A dog-lover, she married Leo Cooper, a publisher of military history books, in 1961 and they had two children. He died in 2013. Filming for the sequel to "Rivals" began earlier this year. (Reporting by Sam Tabahriti; writing by Sarah Young, Editing by Kate Holton, Alexandra Hudson and Alex Richardson)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: INTERVIEW WITH FORMER ENGLAND RUGBY UNION CAPTAIN LEWIS MOODY / FILE FOOTAGE OF LEWIS MOODY RESENDING WITH FULL SHOTLIST SHOWS: (UNKNOWN LOCATION, ENGLAND, UK (RECENT) (BBC – No use UK) 1. (SOUNDBITE) (English) FORM R ENGLAND RUGBY CAPTIAN., LEWIS MOODY, SAYING: "Two weeks ago, I was diagnosed with Motor Neuron Disease, and I think it's safe to say it came as a fairly sizable shock to all of us, and we were rightly quite emotional about it. But it's so strange because I feel like nothing's wrong, you know, I don't feel ill, I don't feel unwell. Yes, so a sort of strange position to be in, but we've processed lots of emotions over over the last couple of weeks. It's never me that I feel sad for. It's the sort of sadness around having to tell my mum, having to tell the boys. I mean, you know, two brilliant boys. And it was pretty heartbreaking when it. But we sat on the couch in tears. You know, Ethan and Dylan both wrapped up in, you know, and each other. And the dog then jumped over, started licking the tears of our faces, which was rather sweet, but it was without a shadow of doubt, the horriblest, hardest thing I've ever had to do but I'm really grateful we did it." (BAGSHOT, ENGLAND, UK) (FILE – NOVEMBER 18, 2009) (ORIGINALLY 4:3 MATERIAL) (REUTERS) 2. LEWIS MOODY TRAINING WITH ENGLAND TEAM (UNKNOWN LOCATION, ENGLAND, UK (RECENT) (BBC – No use UK) 3. (SOUNDBITE) (English) FORMER ENGLAND RUGBY CAPTIAN., LEWIS MOODY, SAYING: "With Rob (Burrow). And, you know, having witnessed Doddie (Weir) and the brilliant stuff that Kev Sinfield's done, you know, on behalf of Rob and then most recently Ed Slater. So we see it all in the news. You're aware of it. You know, I feel slightly selfish in a way that I've been reluctant to reach out to anyone, to any of those guys, to Ed sorry, because naively or not, I don't know what's right or wrong in this situation we've been through it. And there is a reluctance, maybe an avoidance to look into the future. There's no there's definitely, it's not they don't understand where it's going. We understand that. But there is absolutely a reluctance to look the future in the face for now, for sure.And that's why, you know, selfishly, again, and I actually hate myself and I hate myself is too strong a word. But, you know, the fact that I haven't been able to reach out, you know, to those people that are suffering with it and really, yeah, I feel selfish that I've not been able to accept that and look into the future.But there will be a time when I can and when I can process that and I would like to as well. So if they're watching over me, there's no, I'm just not ready yet." (BAGSHOT, ENGLAND, UK) (FILE – NOVEMBER 18, 2009) (ORIGINALLY 4:3 MATERIAL) (REUTERS) 4. LEWIS MOODY TRAINING WITH ENGLAND TEAM AUCKLAND, NEW ZEALAND (FILE – SEPTEMBER 30, 2011) (REUTERS) 5. MARTIN JOHNSON WITH CAPTAIN LEWIS MOODY STORY: Former England rugby captain Lewis Moody has been diagnosed with motor neurone disease, he said on Monday. Moody, a flanker who was in the team that won the World Cup in 2003 and took over as captain from Steve Borthwick in 2010, retired from the sport in 2012. Hugely popular with fans and team mates for his fearless approach, Moody won seven Premiership titles during a 14-year spell with Leicester. He was capped 71 times by England. "You're given this diagnosis of MND and we're rightly quite emotional about it, but it's so strange because I feel like nothing's wrong," Moody, 47, told the BBC in an interview. There is no cure for MND, a life-shortening illness in which muscles gradually weaken, stiffen and waste, according to the Motor Neurone Disease Association. Scotland's Doddie Weir and rugby league player Rob Burrow have died after battles with the illness in recent years. "I don't feel ill. I don't feel unwell. My symptoms are very minor. I have a bit of muscle wasting in the hand and the shoulder. I'm still capable of doing anything and everything. And hopefully that will continue for as long as is possible." In a statement, Rugby Football Union (RFU) CEO Bill Sweeney said the governing body was "saddened and distressed" to learn of the news. "His contribution to rugby, both on and off the field, reflects the very best of our sport's values," Sweeney added. "Our thoughts are with Lewis and his family and friends at this very difficult time as they come to terms with this diagnosis and I know the entire rugby community stands with them and will support them." (Production: Oliver Regan)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Tim Hepher PRAGUE (Reuters) -Executives from Boeing and Airbus dampened speculation of imminent decisions to replace their best-selling narrowbody models, telling a major audience of investors that it would take time to achieve the required jump in performance. The Wall Street Journal reported last Monday that Boeing was in the early stages of developing a 737 successor. But marketing chief Darren Hulst told the International Society of Transport Aircraft Trading that a launch is "some way off" while a senior Airbus executive said it would "take a bit of time" to achieve the efficiency gains needed to attract the market. The executives were speaking in separate responses to questions on stage during an ISTAT event in Prague on Monday. The world's dominant planemakers have faced record demand for narrowbody models like the 737 and its European competitor, the A320 family. Both were developed decades ago but were refreshed with new engines in the middle of last decade. BOEING 'NOT CLOSE TO LAUNCHING' NEW PLANE The question of when they will launch the next phase of their epic rivalry by introducing an all-new design is one of the main dilemmas facing the aerospace industry, though most analysts agree a launch is unlikely before later this decade. Earlier this year, Boeing CEO Kelly Ortberg met Rolls-Royce to discuss a new engine, according to the WSJ report. "We are never not looking at new technology but we are also not close to launching a new airplane," Hulst, Boeing's vice president for commercial marketing, told the ISTAT conference. An aircraft launch is the stage at which a manufacturer begins development of a specific product and seeks new buyers. In a note to staff last week, Boeing CEO Kelly Ortberg reiterated any new plane would depend on the market, technology and the company itself being ready, FlightGlobal reported. Boeing is saddled with some $50 billion of debt following a safety crisis involving its best-selling 737 MAX model. It meanwhile has four projects awaiting certification: two variants of the MAX and the larger 777-9 passenger jet as well as its sister freight model, collectively known as the 777X. Bloomberg reported last week that the 777X faced a new delay in certification to 2027, bringing cumulative delays to seven years. Hulst said bringing completing pending projects was the main priority before a new model, but did not comment on 777X timing. AIRBUS SAYS EFFICIENCY GOAL WILL TAKE TIME Airbus, which is outselling Boeing, particularly with the larger versions of the A320 family, has expressed interest in radical new engine technology. Airbus Head of Trading and Asset Management Francois Collet told ISTAT any new plane would need to deliver a 25 to 30% jump in efficiency, something that would take "a little bit of time". (Reporting by Tim Hepher; Editing by Emelia Sithole-Matarise)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
